Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Richaaard who wrote (1026)	2/13/2000 3:33:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 4474

You are welcome. As for specific applications ahead, you are right, we will not know for sure until Ariad or its potential partners care to tell us. However, a number of applications seem to be within the reach of more or less known technology or simple adaptations thereof. Of course, an application of ARGENT "failsafe"-like has already been formulated by Ariad to tackle graft-versus-host-disease (GVHD) after bone marrow transplant (BMT). To my knowledge, nothing further has been announced on this since the release of favorable phase I data for the dimerizer (APC something or other) alone; i.e., without gene therapy just yet. As for your thought, although at a simpler level, it has been speculated that some athletes have cheated by using injections of EPO to improve blood oxygenation (from a quick search I found this among many others: weeklywire.com - look for the reference to EPO). Because this is a human protein it may be very hard to detect. Not sure this use has contributed much to AMGN's bottom line, though -g- PB